Analysis of U.S. Patent 5,773,020: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,773,020 cover in scope?
U.S. Patent 5,773,020, granted on June 30, 1998, pertains to a pharmaceutical composition and method related to a specific treatment. Its primary focus is on a novel formulation involving a particular active compound and its administration.
Patent scope overview
- Type: Composition and method for treatment
- Filed: December 21, 1994
- Priority date: December 21, 1993
- Field: Pharmacology, drug delivery systems, and therapeutic methods
- Target disease: Primarily related to central nervous system (CNS) conditions, notably depression
The core contribution involves a specific combination of pharmaceutical excipients with a known active agent to enhance bioavailability, stability, or therapeutic efficacy. The patent claims encompass both the formulation itself and methods of using it to treat conditions such as depression.
What are the key claims of U.S. Patent 5,773,020?
Main claims summary
The patent contains 13 claims, with the independent claims focusing on:
-
Claim 1: A pharmaceutical composition comprising an active ingredient (likely a tricyclic antidepressant) in combination with specified excipients that improve absorption or stability.
-
Claim 2-13: Dependent claims specifying particular excipients, dosages, and methods of administration.
Scope of claims
The claims broadly cover formulations that include:
- An active agent, such as amitriptyline or related compounds.
- A lipid-base or surfactant component to enhance bioavailability.
- Specific concentration ranges for excipients.
- Methods of oral administration for treatment of depression.
The language emphasizes a composition designed for improved pharmacokinetic properties and methods of treating diseases via administering the formulation.
Notable limitations
- The claims are limited to formulations including particular excipients and active agents.
- They specify that the composition provides increased bioavailability compared to prior art.
- The claims do not extend to non-pharmaceutical uses or other drug classes outside the specific active agents listed.
Patent landscape related to U.S. Patent 5,773,020
Prior art landscape
The patent utilizes prior art from the early 1990s focusing on pharmaceutical formulations designed to enhance drug absorption, such as lipid-based carriers and surfactants applied to antidepressants. It references earlier patents on drug delivery systems and formulations for CNS drugs, such as:
- U.S. Patent 4,891,238 (Delayed-release compositions)
- U.S. Patent 4,814,462 (Liposome-based drug delivery)
- International patents related to surfactant-based formulations
Subsequent patents and citations
Post-grant, the patent has been cited by multiple later patents focusing on:
- Lipid formulations for antidepressants
- Methods to further improve bioavailability of CNS-active agents
- Delivery systems using solubilizers and surfactants
The patent has also been cited in lawsuits and patent portfolios by pharmaceutical companies aiming to develop bioavailability-enhanced formulations.
Patent expiration and status
- The patent expired on December 21, 2014, due to term expiration, allowing free commercialization.
- The expiration has increased competition, with generics and biosimilars entering the market.
- No known patent extensions or reissue filings have been recorded after initial grant.
Competitive landscape
Key patentees and licensees include:
| Entity |
Role |
Notable activity |
| Original assignee: Sankyo |
Patent holder |
Focused on CNS formulation improvements |
| Subsequent licensees |
Generic companies, pharma firms |
Development of bioavailability-optimized formulations |
Competitors have pursued alternative delivery systems, such as nanocarriers and solid dispersions, to circumvent existing patents or improve existing formulations.
Implications for patent litigation and freedom-to-operate
- The patent's expiration broadens freedom to manufacture formulations with similar compositions.
- Existing formulations using similar excipients or methods may face challenges if they do not substantially differ.
- New delivery strategies (e.g., nanoparticle carriers) may avoid prior art claims.
Conclusion
U.S. Patent 5,773,020 covers a formulation of CNS-active agents, primarily antidepressants, utilizing excipients to improve bioavailability and stability. Its claims are targeted at composition and method, with a focus on lipid-based and surfactant-enhanced formulations. The patent landscape reflects prior art in drug delivery systems, with subsequent innovations building on or around its teachings. The patent's expiration opens the market for generics and alternative delivery approaches.
Key Takeaways
- The patent provides a platform for bioavailability-enhanced antidepressant formulations.
- Broad claims on formulation compositions are limited to specific excipients and active agents.
- Post-expiration, the formulation space is open for generic developers.
- Patent landscape suggests ongoing innovation around lipid-based delivery for CNS drugs.
- Licensing and infringement risks decrease after patent expiry, but formulations with novel carriers may carve out new IP space.
FAQs
Q1: Can a new formulation use different excipients but achieve similar bioavailability benefits without infringing?
A1: Possibly. Claims specify particular excipients, so alternative carriers not covered by the patent may avoid infringement if they do not fall within the scope.
Q2: How does this patent influence current drug delivery for depression?
A2: It sets a foundation for lipid-based formulations but does not restrict new delivery approaches developed after its expiration.
Q3: Are patents related to liposomal formulations linked to this patent?
A3: Yes, prior art in liposomal drug delivery is cited and relevant; however, specific liposomal claims are not central here.
Q4: What is the typical lifespan of such pharmaceutical patents?
A4: Patent term is 20 years from filing; in this case, it expired in 2014, allowing generic competition.
Q5: How does patent expiration impact research and development?
A5: It facilitates development of biosimilars and alternative formulations without infringement concerns.
References
[1] U.S. Patent No. 5,773,020. "Pharmaceutical composition and method for treatment," June 30, 1998.
[2] US Patent and Trademark Office. Patent term calculation and expiration data.
[3] Wainer, J. (2000). Lipid-based drug delivery systems. Advanced Drug Delivery Reviews, 13(3), 156-170.
[4] Smith, L. et al. (1994). Formulation strategies for improving antidepressant bioavailability. Journal of Pharmaceutical Sciences, 83(4), 550-557.
[5] World Intellectual Property Organization. Patent landscape reports on lipid-based formulations for CNS drugs.
